These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34089852)

  • 41. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients.
    Lin D; Yang HI; Nguyen N; Hoang J; Kim Y; Vu V; Le A; Chaung K; Nguyen V; Trinh H; Li J; Zhang J; Hsing A; Chen CJ; Nguyen MH
    Aliment Pharmacol Ther; 2016 Oct; 44(8):846-55. PubMed ID: 27549411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients.
    Kim DS; Park SY; Kim BK; Park JY; Kim DY; Han KH; Lee YR; Tak WY; Kweon YO; Jung I; Han M; Kim EH; Ahn SH; Kim SU
    J Korean Med Sci; 2021 Apr; 36(16):e105. PubMed ID: 33904261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States.
    Tong MJ; Hsien C; Hsu L; Sun HE; Blatt LM
    Hepatology; 2008 Oct; 48(4):1070-8. PubMed ID: 18688879
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reasons to consider early treatment in chronic hepatitis B patients.
    Koffas A; Petersen J; Kennedy PT
    Antiviral Res; 2020 May; 177():104783. PubMed ID: 32217150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B.
    Kamalapirat T; Yingcharoen K; Ungtrakul T; Soonklang K; Dechma J; Chunnuan P; Kusuman P; Pothijaroen C; Tawpa J; Cheirsilpa K; Auewarakul C
    J Viral Hepat; 2021 Jul; 28(7):1034-1041. PubMed ID: 33880807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B.
    Wang C; Chen V; Vu V; Le A; Nguyen L; Zhao C; Wong CR; Nguyen N; Li J; Zhang J; Trinh H; Nguyen MH
    Medicine (Baltimore); 2016 Aug; 95(35):e4744. PubMed ID: 27583921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy.
    Seo YS; Kim MN; Kim SU; Kim SG; Um SH; Han KH; Kim YS
    Medicine (Baltimore); 2016 Mar; 95(12):e2985. PubMed ID: 27015173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients.
    Poh Z; Goh BB; Chang PE; Tan CK
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):638-43. PubMed ID: 25831135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
    Tseng TC; Choi J; Nguyen MH; Peng CY; Siakavellas S; Papatheodoridis G; Wang CC; Lim YS; Lai HC; Trinh HN; Wong C; Wong C; Zhang J; Li J; Kao JH
    Hepatol Int; 2021 Feb; 15(1):105-113. PubMed ID: 33547557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis.
    Liu K; Choi J; Le A; Yip TC; Wong VW; Chan SL; Chan HL; Nguyen MH; Lim YS; Wong GL
    Aliment Pharmacol Ther; 2019 Nov; 50(9):1037-1048. PubMed ID: 31524304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B.
    Lee HW; Cho YY; Lee H; Lee JS; Kim SU; Park JY; Kim DY; Ahn SH; Kim BK; Park SY
    Hepatol Int; 2021 Oct; 15(5):1083-1092. PubMed ID: 34402025
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
    Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
    Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
    J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The natural history of chronic hepatitis B: a retrospective study.
    Wu GC; Zhou WP; Zhao YR; Guo SH; Wang ZY; Zou SB; Zhang QH; Ren H; Huang AL; Zhang DF
    Hepatobiliary Pancreat Dis Int; 2003 Nov; 2(4):566-70. PubMed ID: 14627521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.
    Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M;
    Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic hepatitis B virus infection in Asian countries.
    Merican I; Guan R; Amarapuka D; Alexander MJ; Chutaputti A; Chien RN; Hasnian SS; Leung N; Lesmana L; Phiet PH; Sjalfoellah Noer HM; Sollano J; Sun HS; Xu DZ
    J Gastroenterol Hepatol; 2000 Dec; 15(12):1356-61. PubMed ID: 11197043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.